234 related articles for article (PubMed ID: 31589171)
1. The cause and pathogenesis of hemolytic transfusion reactions in sickle-cell disease.
Pirenne F
Curr Opin Hematol; 2019 Nov; 26(6):488-494. PubMed ID: 31589171
[TBL] [Abstract][Full Text] [Related]
2. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
Balbuena-Merle R; Hendrickson JE
Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806
[TBL] [Abstract][Full Text] [Related]
3. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.
Gardner K; Hoppe C; Mijovic A; Thein SL
Br J Haematol; 2015 Sep; 170(6):745-56. PubMed ID: 25967919
[TBL] [Abstract][Full Text] [Related]
4. Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease.
Gerritsma J; Bongaerts V; Eckhardt C; Heijboer H; Nur E; Biemond B; van der Schoot E; Fijnvandraat K;
Br J Haematol; 2022 Feb; 196(3):769-776. PubMed ID: 34632580
[TBL] [Abstract][Full Text] [Related]
5. Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease.
Fasano RM; Miller MJ; Chonat S; Stowell SR
Transfus Clin Biol; 2019 May; 26(2):94-98. PubMed ID: 30837199
[TBL] [Abstract][Full Text] [Related]
6. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP
Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
[TBL] [Abstract][Full Text] [Related]
7. Alloimmunization and hyperhemolysis in sickle cell disease.
Pirenne F; Pondarré C
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):653-659. PubMed ID: 38066873
[TBL] [Abstract][Full Text] [Related]
8. The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction.
Roumenina LT; Bartolucci P; Pirenne F
Transfus Med Rev; 2019 Oct; 33(4):225-230. PubMed ID: 31672341
[TBL] [Abstract][Full Text] [Related]
9. Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease: A Case Series.
Alwaheed AJ; Alqatari SG; AlSulaiman AS; AlSulaiman RS
Am J Case Rep; 2022 Jan; 23():e934681. PubMed ID: 34983921
[TBL] [Abstract][Full Text] [Related]
10. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.
Pirenne F; Yazdanbakhsh K
Blood; 2018 Jun; 131(25):2773-2781. PubMed ID: 29724898
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of alloimmunization in sickle cell disease.
Hudson KE; Fasano RM; Karafin MS; Hendrickson JE; Francis RO
Curr Opin Hematol; 2019 Nov; 26(6):434-441. PubMed ID: 31483335
[TBL] [Abstract][Full Text] [Related]
12. Impact of Red Blood Cell Antigen Matching on Alloimmunization and Transfusion Complications in Patients with Sickle Cell Disease: A Systematic Review.
Fasano RM; Meyer EK; Branscomb J; White MS; Gibson RW; Eckman JR
Transfus Med Rev; 2019 Jan; 33(1):12-23. PubMed ID: 30122266
[TBL] [Abstract][Full Text] [Related]
13. Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR).
Thonier V
Transfus Clin Biol; 2019 May; 26(2):102-108. PubMed ID: 30885514
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for hemolytic transfusion reactions resulting from ABO and minor red cell antigen incompatibility: From mislabeled samples to stem cell transplant and sickle cell disease.
Gehrie EA; Savani BN; Booth GS
Blood Rev; 2021 Jan; 45():100719. PubMed ID: 32561028
[TBL] [Abstract][Full Text] [Related]
15. Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.
Chonat S; Arthur CM; Zerra PE; Maier CL; Jajosky RP; Yee MEM; Miller MJ; Josephson CD; Roback JD; Fasano R; Stowell SR
Transfus Clin Biol; 2019 May; 26(2):130-134. PubMed ID: 30979566
[TBL] [Abstract][Full Text] [Related]
16. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes.
Habibi A; Mekontso-Dessap A; Guillaud C; Michel M; Razazi K; Khellaf M; Chami B; Bachir D; Rieux C; Melica G; Godeau B; Galacteros F; Bartolucci P; Pirenne F
Am J Hematol; 2016 Oct; 91(10):989-94. PubMed ID: 27348613
[TBL] [Abstract][Full Text] [Related]
17. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions.
Merle NS; Boudhabhay I; Leon J; Fremeaux-Bacchi V; Roumenina LT
Transfus Clin Biol; 2019 May; 26(2):116-124. PubMed ID: 30879901
[TBL] [Abstract][Full Text] [Related]
18. Can we better predict delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease?
Adkins BD; Sharma D; Eichbaum Q
Transfus Apher Sci; 2020 Apr; 59(2):102681. PubMed ID: 31831326
[TBL] [Abstract][Full Text] [Related]
19. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
Ferlis M; Lipato T; Roseff SD; Smith WR
Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
[TBL] [Abstract][Full Text] [Related]
20. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.
Narbey D; Habibi A; Chadebech P; Mekontso-Dessap A; Khellaf M; Lelièvre JD; Godeau B; Michel M; Galactéros F; Djoudi R; Bartolucci P; Pirenne F
Am J Hematol; 2017 Dec; 92(12):1340-1348. PubMed ID: 28924974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
